Abemaciclib

CAS 1231929-97-7 17 current recordsSmall Molecule

Who holds supplier records for Abemaciclib? 17 organisations hold a current record for Abemaciclib: an active US FDA Type II Drug Master File. Recorded organisation countries for current records: India (7), China (4), Taiwan (2), Hungary (1) and 1 other country (1); not recorded for 2.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Abemaciclib: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/abemaciclib

Reading the evidence

  • 17 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • 11 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Abemaciclib expires 11 Jul 2039. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (17)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Abemaciclib. Country is the organisation's recorded country, not necessarily the manufacturing site.

India7China4Taiwan2Hungary1Poland1Country not recorded for 2
Need Abemaciclib sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (4 listed products contain Abemaciclib). The latest listed patent expires 11 Jul 2039. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Overview

Abemaciclib is an orally administered selective inhibitor of cyclin-dependent kinases 4 and 6, which are key regulators of the cell cycle. It is primarily used in the treatment of hormone receptor-positive, HER2-negative breast cancer.

Chemical identity

IUPAC name
N-[5-[(4-ethylpiperazin-1-yl)methyl]-2-pyridinyl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine
Canonical SMILES
CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F
InChIKey
UZWDCWONPYILKI-UHFFFAOYSA-N
Synonyms
LY-2835219, Verzenio, ly-2835210, ly2835210, ly2835219

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Kinase Inhibitor
Mechanism of action
Kinase Inhibitors

Therapeutic areas

OncologyBreast CancerCell Cycle Inhibition

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Abemaciclib?

17 organisations hold an active US FDA Type II Drug Master File or a CEP for Abemaciclib: MSN Laboratories Private Limited (India), Alembic Pharmaceuticals Limited (India), BEIJING HOPE PHARMACEUTICAL CO LTD, BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITED (India), CHANGZHOU PHARMACEUTICAL FACTORY (China), Cipla Limited (India), Dr. Reddy's Laboratories Ltd. (India) and Egis Pharmaceuticals PLC (Hungary), and 9 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Abemaciclib Drug Master Files are active?

MSN Laboratories Private Limited (DMF 40612, 34714), Alembic Pharmaceuticals Limited (DMF 44268), BEIJING HOPE PHARMACEUTICAL CO LTD (DMF 43239), BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITED (DMF 44410), CHANGZHOU PHARMACEUTICAL FACTORY (DMF 41480), Cipla Limited (DMF 42482), Dr. Reddy's Laboratories Ltd. (DMF 40799) and Egis Pharmaceuticals PLC (DMF 43680) and 9 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

Does the FDA Orange Book list patents for products containing Abemaciclib?

Yes. The latest patent listed for an approved US product containing Abemaciclib expires 11 Jul 2039, across 4 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Abemaciclib supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Abemaciclib?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.